ArticleCureus2024
Risk Stratification for Autoimmune Hemolytic Anemia in Children With Pediatric Transfusion-Dependent Thalassemia.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to identify the risk factors for autoimmune hemolytic anemia (AIHA) in children with transfusion-dependent thalassemia (TDT). Methodology This cross-sectional study was conducted at the Department of Child Health, Khyber Teaching Hospital, Peshawar, Pakistan, from March 25, 2024, to September 25, 2024. A total of 300 patients under 18 years of age, diagnosed with TDT, were included in the study. Relevant demographic, clinical, and laboratory investigations were conducted for each patient, with AIHA diagnosed based on the Coombs test. Risk factors, including demographic data, disease characteristics, transfusion history, clinical factors, and laboratory parameters, were recorded and analyzed. The significance of these risk factors was assessed by using the chi-square test for categorical variables and the independent t-test for continuous variables, comparing Coombs test-compatible and incompatible patients. A p-value of less than 0.05 was considered statistically significant. Results The mean±SD age of participants in this study was 6.82±4.2 years with an age range of one to 16 years. The male gender was 56.33%. The results of the Coombs test showed that 48.66% of these children had developed AIHA. The comparison between incompatible and compatible patients at Coombs test showed that age of patients (5.87±3.93 vs. 7.68±4.28 years, p = 0.00), age at the time of diagnosis (2.21±0.99 vs. 4.64±3.03 years, p = 0.00), age at the time of first infusion (3.05±1.28 vs. 5.49±3.2 years, p = 0.00), transfusion interval < 3 weeks (48.6% vs. 37%, p = 0.04) and duration of transfusion (2.87±3.2 vs. 2.21±1.93 years, p = 0.03) were the significant risk factors in the development of AIHA. Conclusion The patient's age, age at diagnosis, age at the time of first transfusion, the transfusion interval, and the duration of blood transfusion are the significant risk factors influencing the development of AIHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.